RxDoctor Payments Data

Lee Gray, MD

Nephrology · Huntersville, NCNPI 1114145554

Payments from drug & device makers

$884in general payments, 2019–2025

Across 38 payments — averaging $23.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$201
  • Sanofi$140
  • GRT US Holding, Inc.$117
  • Collegium Pharmaceutical, Inc.$112
  • Scilex Pharmaceuticals Inc.$70
  • Daiichi Sankyo Inc.$41
  • plus $203 from 10 others

What the payments were for

  • Food & beverage$87899%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$884 in reported general payments places this provider in the 40th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$56,384
Medicare patients
85
Services billed
772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$12,342
Xtampza ErOxycodone Myristate19$11,178
Hysingla ErHydrocodone Bitartrate15$10,768
MovantikNaloxegol Oxalate20$10,613
SuboxoneBuprenorphine Hcl/Naloxone Hcl26$10,473
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl96$8,286
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen278$7,835
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen254$6,810
BelbucaBuprenorphine Hcl15$6,783
Lidocaine26$3,295
Oxycodone Hcl123$2,069
Pregabalin114$1,971
Gabapentin149$1,430
Morphine Sulfate ErMorphine Sulfate41$1,151
Omeprazole42$1,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$112$17,96134 claims
PfizerEliquis$29$12,34215 claims
Indivior Inc.Suboxone$36$10,47326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 366 nephrology providers in North Carolina.

Other nephrology in Huntersville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →